Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Other Accumulated Expenses: 2018-2025

  • China SXT Pharmaceuticals' Other Accumulated Expenses rose 86.53% to $674,391 in Q1 2025 from the same period last year, while for Mar 2025 it was $674,391, marking a year-over-year increase of 86.53%. This contributed to the annual value of $674,391 for FY2025, which is 86.53% up from last year.
  • As of Q1 2025, China SXT Pharmaceuticals' Other Accumulated Expenses stood at $674,391, which was up 86.53% from $361,543 recorded in Q1 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Other Accumulated Expenses peaked at $1.2 million during Q1 2022, and registered a low of $361,543 during Q1 2024.
  • In the last 3 years, China SXT Pharmaceuticals' Other Accumulated Expenses had a median value of $674,391 in 2025 and averaged $608,389.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Other Accumulated Expenses skyrocketed by 184.90% in 2021 and then plummeted by 54.19% in 2024.
  • China SXT Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $819,677 in 2021, then skyrocketed by 41.80% to $1.2 million in 2022, then crashed by 32.10% to $789,232 in 2023, then slumped by 54.19% to $361,543 in 2024, then soared by 86.53% to $674,391 in 2025.
  • Its Other Accumulated Expenses was $674,391 in Q1 2025, compared to $361,543 in Q1 2024 and $789,232 in Q1 2023.